Empowered Funds’s Corcept Therapeutics CORT Stock Holding History

Empowered Funds’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$291K	Sell	3,341 -93,954	-97%	-$5.67M	﹤0.01%	1871
2026 Q1	$3.92M	Buy	+97,295	New	+$3.64M	0.03%	747
2025 Q3	–	Sell	-2,852	Closed	-$209K	–	1844
2025 Q2	$209K	Sell	2,852 -119,493	-98%	-$8.66M	﹤0.01%	1631
2025 Q1	$14M	Buy	122,345 +81,297	+198%	+$4.95M	0.2%	92
2024 Q4	$2.07M	Buy	41,048 +2,507	+7%	+$131K	0.03%	723
2024 Q3	$1.78M	Buy	+38,541	New	+$1.37M	0.03%	713
2024 Q1	–	Sell	-41,067	Closed	-$1.33M	–	1383
2023 Q4	$1.33M	Buy	+41,067	New	+$1.13M	0.03%	663
2020 Q3	–	Sell	-174,010	Closed	-$2.93M	–	120
2020 Q2	$2.93M	Buy	+174,010	New	+$2.44M	1.13%	14

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Empowered Funds's CORT Position: Q2 2026 in Review

Empowered Funds reduced its Corcept Therapeutics (CORT) stake by 97% in Q2 2026, selling an estimated $5.67M and leaving 3,341 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Empowered Funds first reported a position in CORT in Q2 2020 and has held it in 8 quarters since. The position peaked at $14M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Empowered Funds held 3,341 shares of Corcept Therapeutics worth $291K as of Q2 2026.
Empowered Funds sold 93,954 Corcept Therapeutics shares in Q2 2026, an estimated $5.67M.
Corcept Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #1871 holding.
Empowered Funds first reported a position in Corcept Therapeutics in Q2 2020 and has held it in 8 quarters since.
Empowered Funds's Corcept Therapeutics position peaked at $14M in Q1 2025.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.